Last week’s Dow collapse wasn’t really about China or a recession. It was plain old slow growth. Biotech stocks are one remedy.

The president’s foolhardy foreign policy and wanton spending have investors fleeing to foreign exchanges. It’s time to join them.

It seemed a good match: on one side, old-fashioned oligarchs looking to modernize Wal-Mart’s image; on the other, the big-city types who could make a fortune doing it. By the time it was over, a Madison Avenue heavy had been summoned to Arkansas to answer questions about his splashy lifestyle, and nobody was happy except the lawyers.

An equity shortage, a new M&A boom, a weak dollar, and lower interest rates point to another year of big winnings on Wall Street.

The man who’s revolutionizing the New York Stock Exchange is a shrewd, calculating technocrat who turned its iconic trading floor into a machine—but he’s also the affable mensch who is managing to persuade the traders to go along with their own extinction.

“We’re not cranks, unless letting powerful people do whatever they want, without any public review or regard to law, makes you a crank. That sounds more like a citizen to me—a New Yorker,” Goldstein says.

This year, the Dow Jones cleared the 12,000 bar for the first time, the Standard & Poor’s 500 climbed to five-year highs, and the city’s unemployment rate hit a 30-year low. That’s nothing. Wait until you see what’s going to happen next.

NYSE sure looked nice.

To figure out how much you should give, it helps to know what other people are giving. We surveyed 60 workers in New York’s service sector about what they’ve gotten in the past and what they’re expecting this month.

The real problem isn’t the global megaretailer’s rapacious image. It’s the company’s flagging business fortunes.